Modified carfilzomib dosing is associated with improved treatment responses and longer time on treatment in patients with multiple myeloma

Haematologica. 2023 Dec 1;108(12):3477-3479. doi: 10.3324/haematol.2022.282521.

Affiliations

¹ Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210. Abdullah.Khan@osumc.edu.
² Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210.

No abstract available

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Dexamethasone / therapeutic use
Humans
Multiple Myeloma* / drug therapy
Multiple Myeloma* / etiology
Oligopeptides
Treatment Outcome

Substances

carfilzomib
Oligopeptides
Dexamethasone